Saturday, March 2, 2024

CATEGORY

Pfizer

A New Horizon for Ulcerative Colitis Patients in Europe with Pfizer’s Latest Oral Therapy Approval

Pfizer Inc. is thrilled to announce that VELSIPITY® (etrasimod), the first oral therapy of its kind for ulcerative colitis (UC), has received marketing authorization...

Pfizer/BioNTech COVID-19 Vaccine Available for Private Purchase in the UK

Starting in March, residents of Great Britain will have the unique opportunity to purchase the latest Omicron-specific Pfizer/BioNTech COVID-19 vaccine, known as Comirnaty, directly...

To Improve Cancer Care in Underrepresented Communities, ACS and Pfizer Launch $15M Initiative

The American Cancer Society (ACS) and Pfizer Inc. have jointly launched a three-year initiative called "Change the Odds: Uniting to Improve Cancer Outcomes™" to...

Urothelial Cancer Treatments PADCEV® and KEYTRUDA® Were Validated Type II Variation Applications by EMA

The European Medicines Agency (EMA) validated a Type II variation application for PADCEV® (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) as a first-line therapy...

TIVDAK® for Cervical Cancer Treatment Accepted by FDA

Pfizer Inc. and Genmab A/S have announced a significant development in the treatment of recurrent or metastatic cervical cancer with the U.S. Food and...

Prostate Cancer Combination Treatment TALZENNA® and XTANDI® Receives European Commission Approval

Pfizer Inc. has announced a significant development in the treatment of metastatic castration-resistant prostate cancer (mCRPC) with the European Commission’s approval of TALZENNA® (talazoparib)...

SpringWorks’ Therapy for Desmoid Tumors Receives FDA Approval

SpringWorks Therapeutics, a Pfizer spin-out, has achieved its maiden FDA approval with Ogsiveo (nirogacestat), marking a groundbreaking advancement in treating desmoid tumors. This oral...

Pfizer and BioNTech Report Favorable Topline Results for mRNA Dual Vaccine Targeting Influenza and COVID-19

Pfizer and BioNTech have reported encouraging results from their Phase 1/2 clinical trial, which evaluated the safety, tolerability, and immunogenicity of mRNA-based combination vaccines...

Latest news

Sticky Image